Publicacións (238) Publicacións de Jesús María Hernández Rivas

2024

  1. Aggressive systemic mastocytosis with the co-occurrence of PRKG2::PDGFRB, KAT6A::NCOA2, and RXRA::NOTCH1 fusion transcripts and a heterozygous RUNX1 frameshift mutation

    Cancer Genetics, Vol. 284-285, pp. 5-11

  2. Chronic lymphocytic leukemia patients with chromosome 6q deletion as the sole cytogenetic abnormality display a high frequency of RPS15 mutations and have a poor prognosis

    American Journal of Hematology

  3. Covering Hierarchical Dirichlet Mixture Models on binary data to enhance genomic stratifications in onco-hematology

    PLoS Computational Biology, Vol. 20, Núm. 2

  4. Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial

    Haematologica, Vol. 109, Núm. 2, pp. 543-552

  5. Gut microbiota and its relationship with early vascular ageing in a Spanish population (MIVAS study)

    European Journal of Clinical Investigation, Vol. 54, Núm. 9

  6. Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes

    Nature Communications, Vol. 15, Núm. 1

  7. Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis

    Leukemia

  8. Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

    HemaSphere

  9. Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial

    The Lancet Haematology, Vol. 11, Núm. 9, pp. e659-e670

  10. Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study

    Leukemia, Vol. 38, Núm. 9, pp. 1929-1937

  11. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

    American Journal of Hematology, Vol. 99, Núm. 4, pp. 586-595

  12. The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis

    American Journal of Hematology

2023

  1. A t(4;13)(q21;q14) translocation in B-cell chronic lymphocytic leukemia causing concomitant homozygous DLEU2/miR15a/miR16-1 and heterozygous ARHGAP24 deletions

    Cancer Genetics, Vol. 272-273, pp. 16-22

  2. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)

    Leukemia

  3. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

    Leukemia, Vol. 37, Núm. 2, pp. 339-347

  4. Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases

    Frontiers in immunology, Vol. 14, pp. 1310211

  5. Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols

    HemaSphere

  6. Implementación de flipped learning y evaluación entre iguales en la enseñanza de la genética clínica mediante las redes sociales

    Proceedings 2nd international congress: education and knowledge

  7. Lifestyles, arterial aging, and its relationship with the intestinal and oral microbiota (MIVAS III study): a research protocol for a cross-sectional multicenter study

    Frontiers in public health, Vol. 11, pp. 1164453

  8. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

    HemaSphere, Vol. 7, Núm. 1, pp. E818